Temple 8 Research
AI Buildout, Macro & Energy Infrastructure Research
Aehr Test Systems has the best burn-in story but the most stretched valuation, ranking last for upside behind Trio-Tech and inTEST. Nvidia's Vera Rubin makes burn-in non-negotiable: 16-high HBM4 stacks mean one latent defect can ruin a GPU, 1.2kW 3nm chips need ovenless burn-in with liquid-cooled heads, and a single failed GPU can cost hyperscalers millions in lost compute, so they now demand 100% burn-in rates. x.comÂ
Aehr remains a concentrated, expensive way to own wafer-level photonics burn-in: its 10-K says silicon-photonics customers primarily drove that revenue growth, and FY2027 guidance of $130m-$150m could nearly triple FY2026 sales, yet shares value it at about 20x the guide. Teradyne's acquired photonic-chip test business is not material to its much larger sales; Aehr's top five customers provided 70% of FY2026 revenue, so orders matter more than the headline CPO opportunity. x.comÂ
Aehr Test Systems' valuation looks ahead of its fundamentals after a strong turnaround quarter. Q4 FY2026 revenue rose 33% to $18.8 million with a return to GAAP profit, bookings hit a record $60.7 million and effective backlog topped $100.6 million. FY2027 guidance of $130-150 million implies 160-200% growth, so the post-earnings run prices in high expectations that depend on shipping FOX-XP systems on schedule without margin erosion. TRT is preferred for now. x.com x.comÂ
Aehr Test Systems' selloff has been excessive, despite concern about Teradyne expanding into burn-in, given where the two actually compete, as @LIWEI_TWCapital's comparison shows. x.comÂ
Aehr Test Systems' addressable market looks tiny compared with 200 other AI companies, making it unattractive. x.comÂ
Aehr Test Systems' very lumpy machine sales typically make for a poor business model. x.comÂ
Aehr Test Systems stands to benefit because testing is a bottleneck to scaling AI chips. Testing demand is about to surge. Investors did not question its price-to-sales ratio at 120, despite the current P/S objection. x.com x.comÂ
Aehr Test Systems is a case of narrative running ahead of the numbers. The bull case is reasonable: a young company with a strong position in silicon carbide burn-in, genuine hyperscaler interest in AI chip burn-in and room to expand into memory and logic. But the latest quarter showed revenue down 43% year over year, with no meaningful order conversion from the AI opportunities yet. Until revenue improves and orders come through more clearly, the story stays ahead of the fundamentals. x.comÂ
Aehr Test Systems is key to AI manufacturing and can even be a bottleneck, but at almost 20x revenue through 2028 at the current price, it is stratospherically priced. The risk is giant if something goes wrong for the company or for the AI ramp, and even a slowdown could be deadly at such high valuations. Tech moats are not the same as financial moats. x.comÂ
Aehr Test Systems stands to benefit as testing takes a larger share of expanding semiconductor capex. Teradyne CEO Greg Smith says test's share of semiconductor capex rose from 6.4% in 2025 to 8.1% in the first eight months of 2026, with conditions favorable for prolonged ATE growth. Data-center reliability is pushing testing upstream from systems toward packages and wafers, where Aehr dominates wafer-level burn-in. Aehr lacks a dedicated CPU segment. x.comÂ
Teradyne is a solid core position for the broader semiconductor test theme because it is much more diversified than a concentrated wafer-level burn-in bet such as Aehr Test Systems. x.comÂ